Active Ingredient(s): Vorapaxar Sulfate
FDA Approved: * May 8, 2014
Pharm Company: * MERCK SHARP DOHME
Category: Heart (Cardiac)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zontivity Overview

Vorapaxar (brand name Zontivity, formerly known as SCH 530348) is a thrombin receptor (protease-activated receptor, PAR-1) antagonist based on the natural product himbacine, discovered by Schering-Plough and developed by Merck & Co.[2] Contents 1 Medical uses 2 Contraindications 3 Drug interactions 4 Dose adjustment 5 Mechanism of action 6 Storage 7 History 8 References 9 External links Medical uses Vorapaxar is used for persons with a history of myocardial infarcti...

Read more Zontivity Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Vorapaxar

Recent Zontivity Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Vorapaxar Sulfate
  • Tablet: 2.08mg, 2.5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Zontivity: (2 results)

Sorted by National Drug Code
  • 0006-0351 Zontivity 2.08 mg Oral Tablet, Film Coated by Merck Sharp & Dohme Corp.
  • 70347-208 Zontivity 2.08 mg Oral Tablet, Film Coated by Aralez Pharmaceuticals Us Inc.

Other drugs which contain Vorapaxar Sulfate or a similar ingredient: (1 result)